Compare Incyte Corporation (INCY) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Oscar Health Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Oscar Health Inc trades at $33.37 (market cap $10.22B). The key difference: Incyte Corporation is far larger — about 2.2× Oscar Health Inc's market cap, and Oscar Health Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Oscar Health Inc for 15 Days on average.
| INCY | OSCR | |
|---|---|---|
Market Cap | $22.85B | $10.22B |
Volume | 1,927,029 | 4,123,394 |
Sector | Health | Health |
52-Week High | $129.93 | $33.81 |
52-Week Low | $83.80 | $10.85 |
Typical Hold Time | 33 Days | 15 Days |
Enterprise Value | $18.35B | $6.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
OSCR trades at $33.1, up 0.58% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 and Q2 2026 earnings beats, with revenue growth from $11.7B in 2025 to a projected $15.3B in 2026, turning to a net profit. Analyst consensus is a $34 price target, with 31% buy ratings. Recent news highlights market share gains and raised 2026 guidance following its Investor Day.
The outlook is positive, driven by execution in the ACA market and new growth avenues, but risks include rising medical costs threatening profitability and a high P/E ratio. The stock offers growth potential if margin expansion continues as guided.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
